EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION
https://doi.org/10.20996/1819-6446-2014-10-5-525-529
Abstract
Aim. To study the efficacy of rosuvastatin in dyslipidemia correction in patients after Q-wave myocardial infarction (Q-MI).
Material and methods. 40 patients (aged 52.7±9.4 years old) were included into the study after 10-14 days of the acute Q-MI onset. Determination of blood lipids profile, alanine and asparagine transaminase levels was included into the initial examination. Rosuvastatin in a fixed dose of 20 mg/day was prescribed to the patients as a part of the standard therapy. Depending on the dynamics of the investigated parameters the individual doses of rosuvastatin were adjusted from 10 to 40 mg/day after 1 month of therapy. Final evaluation of blood lipids profile and transaminase levels was performed in the next 2 months of therapy.
Results. Rosuvastatin 20 mg/day for 1 month in patients with an acute Q-MI provides a significant decrease in low-density lipoprotein (LDL) cholesterol level by 21.4%, and achievement of target levels of this parameter in 59.5% of patients. Rosuvastatin dose adjustment was required in 48.6% of patients after 1 month of therapy. Individually adjusted rosuvastatin doses provided the achievement of LDL cholesterol target levels by the end of the third month of treatment in 91% of patients. Elevated liver transaminase levels were observed in 7.5% of patients after 1 month of treatment. There were no new cases of adverse events after 3 months of therapy.
Conclusion. Rosuvastatin 10-40 mg/day is effective and safe medicine for the treatment of dyslipidemia in patients after acute Q-MI.
About the Authors
R. D. Kurbanov
Republican Specialized Center for Cardiology
Uzbekistan
Uzbekistan
Osie ul. 4, Mirzo Ulugbek district, Tashkent, 100052 Uzbekistan
N. U. Zakirov
Republican Specialized Center for Cardiology
Uzbekistan
Uzbekistan
Osie ul. 4, Mirzo Ulugbek district, Tashkent, 100052 Uzbekistan
Y. G. Kevorkova
Republican Specialized Center for Cardiology
Uzbekistan
Uzbekistan
Osie ul. 4, Mirzo Ulugbek district, Tashkent, 100052 Uzbekistan
N. B. Sayfiddinova
Republican Specialized Center for Cardiology
Uzbekistan
Uzbekistan
Osie ul. 4, Mirzo Ulugbek district, Tashkent, 100052 Uzbekistan
References
1. Atroshchenko E.S. Statins and coronary heart disease. Minsk: OOO Belprint; 2007. Russian (Атрощенко Е.С. Статины и коронарная болезнь сердца. Минск: ООО «Белпринт»; 2007).
2. National guidelines for cardiovascular prevention. Kardiovaskulyarnaya Terapiya i Profilaktika 2011; 10 (6) suppl 2: 3-64. Russian (Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная Терапия и Профилактика 2011; 10 (6) приложение 2: 3-64).
3. La Rosa J.C. Low-density lipoprotein cholesterol reduction: the end is more important than the means. Am J Cardiol 2007;100:240-2.
4. Shepherd J., Hunninghake D.B., Stein E.A. et al. Safety of rosuvastatin. Am J Cardiol 2004;94:882-8.
5. Zakirov NU, Kevorkova YG, Sayfiddinova NB, Kurbanov RD. Efficacy and safety of receiving 20 mg Rozulipa for 1 month in patients after Q-wave myocardial infarction. Meditsinskiy Zhurnal Uzbekistana 2013; 6: 51-5. Russian (Закиров Н.У., Кеворкова Ю.Г., Сайфиддинова Н.Б., Курбанов Р.Д. Эффективность и безопасность приема 20 мг Розулипа в течение 1 месяца у больных, перенесших Q-волновой инфаркт миокарда. Медицинский Журнал Узбекистана 2013; 6: 51-5).
6. Sergienko IV. Tactics of treatment after failure of statin monotherapy. Kardiovaskulyarnaya Terapiya i Profilaktika 2011; 10 (4): 110-6. Russian (Сергиенко И.В. Тактика лечения при неэффективности мо-нотерапии статинами. Кардиоваскулярная Терапия и Профилактика 2011; 10 (4): 110-6).
7. Deedwania P.C., Hunninghake D.B., Bays H.E., Jones P.H., Cain V.A., Blasetto J.W., STELLAR Study Group Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 2005;95:360-6.
8. Rubba P., Marotta G., Gentile M. Efficacy and safety of rosuvastatin in the management of dyslipidemia. Vasc Health Risk Manag 2009; 5: 343-52
Review
For citations:
Kurbanov R.D., Zakirov N.U., Kevorkova Y.G., Sayfiddinova N.B. EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION. Rational Pharmacotherapy in Cardiology. 2014;10(5):525-529. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-5-525-529
Views:
778
.jpg)
Email this article 